Company Overview and News

21
‘Buy’ for bank stocks following Q1 sell-off

2018-05-27 bworldonline
THE GROWTH of banking stocks slowed during the quarter as market volatility sent investors into profit-taking mode despite the sector’s good earnings reports. For this quarter, however, most analysts interviewed have signaled a “buy” on the sector amid expectations of better earnings in the months ahead.
EW UBNC PSKXF CHIB BDOUY RZLLY PBB RCB SECB CKGOY AUB BDOUF BDO SYBJF PNB PHSXY PSE COL PTC

5
EastWest Bank profit drops

2018-05-16 bworldonline
EAST WEST Banking Corp. (EastWest Bank) posted lower net profit in the first quarter on the back of low contributions from its rural bank and security trading arms.
EW PSKXF PHSXY PSE

16
Lenders, e-money issuers set up InstaPay platform

2018-04-23 bworldonline
BANKS and e-money issuers have set up a new clearing house for real-time fund transfers yesterday, with seven lenders now able to process interbank transactions in a matter of seconds.
EW CHIB BDOUY RZLLY RCB SECB CKGOY AUB BDOUF BDO SYBJF PSB PTC

6
Filinvest Development nets P10.3 billion

2018-04-10 bworldonline
FILINVEST Development Corp. (FDC) grew its net profit by more than a fifth last year, buoyed by its banking and property businesses.
FILIY FVSMF EW FDC FLI

5
Security Bank begins P5-B LTNCD offer

2018-04-10 bworldonline
SECURITY BANK Corp. on Tuesday said it started to offer at least P5 billion in long-term negotiable certificates of deposit (LTNCD), part of a bigger fund-raising program.
EW CHIB SYBJF SECB CKGOY

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to PSE:EW / East West Banking Corporation on message board site Silicon Investor.

View from the Center and Left Franklin, Andrews, Kramer u0026 Edelstein
Fake News The New Qualcomm - write what you like thread.
The *NEW* Frank Coluccio Technology Forum News Links and Chart Links
McEwen Mining Mining News of Note
Hewlett Packard Enterprise (HPE) Media Industries: Newspapers, TV, Radio, Movies, Online